7:03AM Vivus announces additional results of phase 3 avanafil study in erectile dysfunction showing efficacy in 15 Minutes (VVUS) 10.21 : Co announces new data from an analysis of the recently completed phase 3 study of avanafil, an investigational drug candidate for the treatment of erectile dysfunction. Patients who attempted intercourse within 15 minutes of dosing were successful 67%, 69% and 72% of the time on 50, 100 and 200 mg of avanafil, respectively, as compared to 29% of the patients on placebo. The previously-disclosed top-line results of the REVIVE study evaluating the safety and efficacy of avanafil in 646 patients showed that all three doses of avanafil met the FDA-defined primary study endpoints by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile and improvements in the International Index of Erectile Function score
surf's up......crikey
